source
- Celcuity reports combo regimen with gedatolisib doubles progression‑free survival odds in late‑stage breast cancerCelcuity announced at ASCO 2026 that its experimental drug gedatolisib, used in a combination regimen, showed a significant improvement in a late‑stage breast cancer trial. The data revealed that…
- Michigan lawmakers introduce bipartisan bill to curb China-U.S. biotech partnershipsA bipartisan group of Michigan legislators has unveiled a new bill aimed at limiting cross-border transactions between Chinese and American biotechnology firms. The proposal, introduced by Rep. Jo…